PURPOSE: The serotonin system is undoubtedly involved in the pathogenesis of major depressive disorder (MDD). More specifically the serotonin transporter (SERT) serves as a major target for antidepressant drugs. There are conflicting results about SERT availability in depressed patients versus healthy controls. We aimed to measure SERT availability and study the effects of age, gender and season of scanning in MDD patients in comparison to healthy controls. METHODS: We included 49 depressed outpatients (mean+/-SD 42.3 +/- 8.3 years) with a Hamilton depression rating scale score above 18, who were drug-naive or drug-free for >or=4 weeks, and 49 healthy controls matched for age (+/-2 years) and sex. Subjects were scanned with single photon emission computed tomography (SPECT) using [(123)I]beta-CIT. SERT availability was expressed as specific to nonspecific binding ratios (BP(ND)) in the midbrain and diencephalon with cerebellar binding as a reference. RESULTS: In crude comparisons between patients and controls, we found no significant differences in midbrain or diencephalon SERT availability. In subgroup analyses, depressed males had numerically lower midbrain SERT availability than controls, whereas among women SERT availability was not different (significant diagnosis x gender interaction; p = 0.048). In the diencephalon we found a comparable diagnosis x gender interaction (p = 0.002) and an additional smoking x gender (p = 0.036) interaction. In the midbrain the season of scanning showed a significant main effect (p = 0.018) with higher SERT availability in winter. CONCLUSION: Differences in SERT availability in the midbrain and diencephalon in MDD patients compared with healthy subjects are affected by gender. The season of scanning is a covariate in the midbrain. The diagnosis x gender and gender x smoking interactions in SERT availability should be considered in future studies of the pathogenesis of MDD.
PURPOSE: The serotonin system is undoubtedly involved in the pathogenesis of major depressive disorder (MDD). More specifically the serotonin transporter (SERT) serves as a major target for antidepressant drugs. There are conflicting results about SERT availability in depressedpatients versus healthy controls. We aimed to measure SERT availability and study the effects of age, gender and season of scanning in MDDpatients in comparison to healthy controls. METHODS: We included 49 depressed outpatients (mean+/-SD 42.3 +/- 8.3 years) with a Hamilton depression rating scale score above 18, who were drug-naive or drug-free for >or=4 weeks, and 49 healthy controls matched for age (+/-2 years) and sex. Subjects were scanned with single photon emission computed tomography (SPECT) using [(123)I]beta-CIT. SERT availability was expressed as specific to nonspecific binding ratios (BP(ND)) in the midbrain and diencephalon with cerebellar binding as a reference. RESULTS: In crude comparisons between patients and controls, we found no significant differences in midbrain or diencephalon SERT availability. In subgroup analyses, depressed males had numerically lower midbrain SERT availability than controls, whereas among womenSERT availability was not different (significant diagnosis x gender interaction; p = 0.048). In the diencephalon we found a comparable diagnosis x gender interaction (p = 0.002) and an additional smoking x gender (p = 0.036) interaction. In the midbrain the season of scanning showed a significant main effect (p = 0.018) with higher SERT availability in winter. CONCLUSION: Differences in SERT availability in the midbrain and diencephalon in MDDpatients compared with healthy subjects are affected by gender. The season of scanning is a covariate in the midbrain. The diagnosis x gender and gender x smoking interactions in SERT availability should be considered in future studies of the pathogenesis of MDD.
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Susan E Best; Philip M Sarrel; Robert T Malison; Marc Laruelle; Sami S Zoghbi; Ronald M Baldwin; John P Seibyl; Robert B Innis; Christopher H van Dyck Journal: Psychopharmacology (Berl) Date: 2005-11-09 Impact factor: 4.530
Authors: A Neumeister; W Pirker; M Willeit; N Praschak-Rieder; S Asenbaum; T Brücke; S Kasper Journal: Biol Psychiatry Date: 2000-01-15 Impact factor: 13.382
Authors: Roger S McIntyre; Deborah Mancini; Beata S Eisfeld; Joanna K Soczynska; Larry Grupp; Jakub Z Konarski; Sidney H Kennedy Journal: Psychoneuroendocrinology Date: 2006-09-05 Impact factor: 4.905
Authors: S J Harrison; A E Tyrer; R D Levitan; X Xu; S Houle; A A Wilson; J N Nobrega; P M Rusjan; J H Meyer Journal: Acta Psychiatr Scand Date: 2015-04-17 Impact factor: 6.392
Authors: Rama Pichika; Monte S Buchsbaum; Ursula Bailer; Carl Hoh; Alex Decastro; Bradley R Buchsbaum; Walter Kaye Journal: Int J Eat Disord Date: 2011-06-13 Impact factor: 4.861
Authors: Louisa J. Steinberg; Mark D. Underwood; Mihran J. Bakalian; Suham A. Kassir; J. John Mann; Victoria Arango Journal: J Psychiatry Neurosci Date: 2019-09-01 Impact factor: 6.186
Authors: Andrea E Tyrer; Robert D Levitan; Sylvain Houle; Alan A Wilson; José N Nobrega; Jeffrey H Meyer Journal: Neuropsychopharmacology Date: 2016-04-18 Impact factor: 7.853
Authors: Jeffrey M Miller; Natalie Hesselgrave; R Todd Ogden; Gregory M Sullivan; Maria A Oquendo; J John Mann; Ramin V Parsey Journal: Biol Psychiatry Date: 2013-03-01 Impact factor: 13.382